[News Brief] Gene Solutions Validates Asia’s First Multi-Cancer Blood Test
Gene Solutions has completed the K-DETEK trial, making SPOT-MAS the first multi-cancer early detection (MCED) blood test in Asia to…
Medical Equipment
[News Brief] Gene Solutions Introduces SPOT-MAS Multi-Cancer Screening in Taiwan
Gene Solutions, in partnership with Gene Health, has launched SPOT-MAS in Taiwan, an AI-driven multi-cancer early detection (MCED) solution designed…
[News Brief] Gene Solutions Presents MRD and Multi-Omics Research at SSO ASM 2025
Gene Solutions showcased advancements in Molecular Residual Disease (MRD) and AI-powered multi-omics technologies at the Singapore Society of Oncology Annual…
[News Brief] Gene Solutions Highlights AI-Powered Multi-Omics at ESMO Asia 2025
Gene Solutions concluded the European Society for Medical Oncology (ESMO) Asia Congress 2025 in Singapore (5–7 December) with a focus…
[News Brief] Lucence and A*STAR’s DxD Hub Collaborate on Multi-Cancer Screening
Lucence and the Diagnostics Development Hub (DxD Hub), a national platform hosted by Singapore’s Agency for Science, Technology and Research…
[News Brief] Lucence Secures MolDX Medicare Coverage for LiquidHALLMARK®
Lucence has announced that its LiquidHALLMARK® ctDNA/ctRNA liquid biopsy test has received Medicare coverage approval through the Molecular Diagnostic Services…
[News Brief] Mayo Clinic Laboratories and Lucence Partner to Expand Cancer Testing
Mayo Clinic Laboratories and Lucence announced a strategic collaboration on 10 January 2025 to increase global access to liquid biopsy…
[News Brief] Agilus and Lucence Partner to Expand Molecular Cancer Testing in India
Agilus Diagnostics and Lucence announced a strategic partnership on 24 February 2025 to integrate liquid biopsy technology into Agilus’ laboratory…
[News Brief] Lucence Demonstrates Improved Cancer Diagnostic Yield at ASCO 2025
Lucence presented clinical data at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago. The studies evaluate a…
[News Brief] Mirxes Lists on HKEX as Southeast Asia’s First Biotech Unicorn
Mirxes listed on the Hong Kong Stock Exchange Main Board on 23 May 2025, reaching a market capitalisation of HK$8.29…